	Association of systemic inflammatory biomarkers with prostate cancer risk: a population-based (NHANES) and clinical validation study. Front Endocrinol (Lausanne) Huang G, Xiao K, Lin S, Lu X. PMID: 41293737 [PubMed - indexed for MEDLINE]
	Brain metastasis from prostate cancer with neurologic symptoms as the first sign: a case report. Aging Male Chen C, Mo C, Zhang S, Shi Y, Ji L, Ning Z, Ding H. PMID: 41292074 [PubMed - indexed for MEDLINE]
	Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study. Int J Urol Sazuka T, Tatsugami K, Shirotake S, Hamamoto S, Nozawa M, Numakura K, Mizokami A, Kondo T, Naito S, Abe T, Ohba K, Kimura G, Onodera S, Yamaguchi K, Uemura H. PMID: 41292059 [PubMed - as supplied by publisher]
	Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer. Sci Rep Kanesaka M, Sazuka T, Kita Y, Fukuhara H, Takaoka N, Sugino Y, Matsushita Y, Mori K, Ieda K, Shimizu Y, Anami T, Tsuchihashi K, Kobayashi M, Tatarano S, Miyake M, Matsui Y, Kitamura H, Nishiyama H, Kimura T, Kobayashi T, Ichikawa T. PMID: 41290935 [PubMed - indexed for MEDLINE]
	JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan. Sci Rep Kobayashi T, Kitamura H, Furukawa Y, Shono M, Ito T, Kikuchi E. PMID: 41290744 [PubMed - indexed for MEDLINE]
	Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence. Nat Commun Soeung M, Yan X, Zanca C, Qian J, Karki M, Duan F, Khan H, Zhang L, Peng DH, Williams M, He R, Chen Z, Perelli L, Chen J, Tidwell RS, Chauhan PK, Le CN, Lam TNA, Bhattacharya N, Shah R, Ho IL, Gay JP, Carrillo CC, Feng N, Le K, Gao G, Perry TL, Mseeh F, Jiang Y, Xu QA, Zacharias NM, Sheth RA, Bathala TK, Rao P, Daw NC, Tripathi DN, Walker CL, Mohammad MM, Zhang J, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav A, Lang W, Arrechedera CA, Clemente LC, Parra ER, Lu H, Haymaker CL, Wistuba II, Futreal A, Viale A, Soth MJ, Jones P, Marszalek JR, Heffernan T, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P. PMID: 41290625 [PubMed - indexed for MEDLINE]
	Gleason Score 3 + 4 (Grade Group 2) Prostate Cancer on Biopsy and Postoperative Pathological Upgrading: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer Wu S, Lin SX, Feldman AS, Wu CL, Dahl DM. PMID: 41290452 [PubMed - as supplied by publisher]
	Response to: "Letter to the Editor Re: A Systematic Review for Health Disparities and Inequities in Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis". Acad Radiol El Khoury CJ, Ros PR. PMID: 41290427 [PubMed - as supplied by publisher]
	[(18)F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results. J Nucl Med Gabler N, Kirchhoff S, Sauter A, Heck M, Lorenzini T, Haller B, Weber WA, Eiber M, Rauscher I. PMID: 41290371 [PubMed - as supplied by publisher]
	Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [(18)F]PSMA-1007 PET/CT and [(18)F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management. J Nucl Med Buch-Olsen KM, Vilstrup MH, Hansen S, Poulsen MH, Holdgaard PC, Zieger KEA, Holm J, Pedersen KT, Hess S, Eiber M, Gerke O, Hildebrandt MG. PMID: 41290368 [PubMed - as supplied by publisher]
	Multi-institutional study on the commissioning and clinical implementation of the TrueBeam enhanced leaf model in the Eclipse treatment planning system. J Appl Clin Med Phys Miyasaka R, Hirai R, Suda Y, Yamauchi R, Mizuno N, Suzuki Y, Igari M, Ohta T, Nakayama H, Arai Y, Sakai K, Hatakeyama K, Miyashita H, Kurooka M, Kawachi T, Hara R. PMID: 41290357 [PubMed - indexed for MEDLINE]
	Targeting prostate cancer through reactive oxygen species: Advances in photothermal and sonodynamic therapies. Nanomedicine Lefta RM, Alshkarchy SS, Ali TF, Jabir MS, Kadhum WR. PMID: 41290108 [PubMed - as supplied by publisher]
	mpMRI-based interpretable machine learning model for predicting castration-resistant prostate cancer risk. Eur J Radiol Shen S, Liu B, Li Y, Zeng Y, Ren S, Yin R, Ma H, Pan S. PMID: 41289721 [PubMed - as supplied by publisher]
	Immune checkpoint inhibitors for high-risk non-muscle invasive bladder cancer: Lessons learnt from the CREST and POTOMAC trials. J Urol González-Padilla DA, Subiela JD, Villacampa-Aubá F. PMID: 41289515 [PubMed - as supplied by publisher]
	Unraveling the carcinogenic mechanisms of benzo[a]pyrene in prostate cancer: a multi-omics approach. Naunyn Schmiedebergs Arch Pharmacol Xiao J, Zheng H, Wu G, Li P, Zhong Q, Lv Q, Chen J, Lai C, Ye D. PMID: 41288678 [PubMed - as supplied by publisher]
	Evaluating Treatment Effects with Patient-Response-Related Outcomes in Comparative Clinical Trials. NEJM Evid Mao L, Tian L, Huang B, Richardson PG, Ludmir EB, Hughes MD, Wei LJ. PMID: 41288427 [PubMed - indexed for MEDLINE]
	The One Big Beautiful Bill Act and the future of prostate cancer care. Cancer Grutman AJ, Pavlovich CP. PMID: 41288347 [PubMed - indexed for MEDLINE]
	Prognostic significance of magnetic resonance imaging-detected extraprostatic extension in localized prostate cancer. Cancer Kumar A, LaBella DA, Snider MC, Acklin-Wehnert SM, Gupta RT, Salama JK, Boyer MJ. PMID: 41288326 [PubMed - indexed for MEDLINE]
	A call for raising public awareness and improving outcomes of penile cancer. Cancer Aydin AM, Albersen M, Spiess PE. PMID: 41288247 [PubMed - indexed for MEDLINE]
	The burden of prostate cancer in Italy from 1990 to 2023, compared to the European Union and the Socio-Demographic Index (SDI) quintile countries: results from the Global Burden of Disease Study 2023. Minerva Urol Nephrol Passera R, Monasta L, Zamagni G. PMID: 41287862 [PubMed - as supplied by publisher]

Articles 1 - 20 / 287639

Page 1 of 14382



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy